A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

Study Summary

The purpose of this Phase 3, randomized, double-blind, placebo-controlled study is to assess the activity and safety of barzolvolimab compared to placebo in participants with cold induced urticaria or symptomatic dermographism who remain symptomatic despite the use of H1-antihistamines.

Conditions

Chronic Inducible Urticaria Cold Urticaria Cold-Induced Urticaria Symptomatic Dermographism

Interventions / Drugs

Barzolvolimab Matching Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment240 participants

Primary Completion—

Lead SponsorCelldex Therapeutics

Data Retrieved2026-04-11 04:09:37.490207+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.